Corporate | 21 November 2005 11:44

Eckert & Ziegler forecasts for 2006: Increase in sales of approx. 20%

Corporate-news transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— Eckert & Ziegler forecasts for 2006: — Increase in sales of approx. 20% — Profits remain stable due to start-up losses in new business fields Berlin, 21 November 2005. Eckert & Ziegler AG (ISIN DE0005659700), a specialist for cancer radiation and medical nuclear imaging products, is planning to expand its range for nuclear medical specialists. The company will be investing several million EUR in developing new products as well as in acquiring the necessary technical authorizations and registrations. These will include various radio-pharmaceutical generic items, such as contrast media for so-called Positron Emission Tomography (PET tracers), synthesis modules to help clinics simplify their own tracer preparation, and a drug for nuclear medical treatment of Spondylitis ankylosans, a serious rheumatic condition. In undertaking these steps, Eckert & Ziegler AG intends to position itself as a new strong partner for nuclear medical specialists especially in Europe, and to participate in the ongoing structural developments in this sector. As major patents expire and new imaging techniques (PET/CT) gain dominance over the coming years, supply and demand structures will change and create opportunities for Eckert & Ziegler AG to utilize its long-term and broad-based expertise in manufacturing and handling isotope technology products in this sector as well. Due to start-up losses associated with entering new fields of activity, the Board expects that profits for 2006 will remain around their level for 2005. Sales in 2006, however, are expected to increase by approximately 20% to around 50 million EUR. New distinctions honor company performance The ongoing growth of Eckert & Ziegler AG has again brought distinctions to the company. In late October, Eckert & Ziegler was a finalist for the Oskar Patzelt Foundation’s “Großer Preis des Mittelstandes”, an award that honors successful mid-sized businesses. The company had previously been selected from a group of 10,000 businesses as one of the “EUROPE’S 500”, i.e. the 500 highest growth companies in Europe. Eckert & Ziegler AG has received this latter distinction for the third time now since 1999. Your contact for enquiries: Eckert & Ziegler AG, Karolin Riehle, Investor Relations Robert-Rössle-Str. 10, D-13125 Berlin Tel.: +49 (0) 30 / 94 10 84-138 http://www.ezag.de End of announcement (c)DGAP 21.11.2005 —————————————————————————— WKN: 565970; ISIN: DE0005659700; Index: Listed: Geregelter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin- Bremen, Düsseldorf, Hamburg, Hannover und Stuttgart